GB201521746D0 - Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers - Google Patents

Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers

Info

Publication number
GB201521746D0
GB201521746D0 GBGB1521746.6A GB201521746A GB201521746D0 GB 201521746 D0 GB201521746 D0 GB 201521746D0 GB 201521746 A GB201521746 A GB 201521746A GB 201521746 D0 GB201521746 D0 GB 201521746D0
Authority
GB
United Kingdom
Prior art keywords
peptides
cancers
combination
immunotherapy against
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1521746.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to GBGB1521746.6A priority Critical patent/GB201521746D0/en
Publication of GB201521746D0 publication Critical patent/GB201521746D0/en
Priority to MX2018005372A priority patent/MX2018005372A/es
Priority to CR20200594A priority patent/CR20200594A/es
Priority to MA42072A priority patent/MA42072A1/fr
Priority to PCT/EP2016/078718 priority patent/WO2017097602A1/en
Priority to CA3005813A priority patent/CA3005813A1/en
Priority to UAA201803219A priority patent/UA124575C2/uk
Priority to CR20180295A priority patent/CR20180295A/es
Priority to CR20200595A priority patent/CR20200595A/es
Priority to MA043399A priority patent/MA43399A/fr
Priority to CR20200596A priority patent/CR20200596A/es
Priority to PE2018000324A priority patent/PE20181075A1/es
Priority to AU2016368981A priority patent/AU2016368981B2/en
Priority to KR1020187013544A priority patent/KR20180086190A/ko
Priority to SG11201801670YA priority patent/SG11201801670YA/en
Priority to CR20200593A priority patent/CR20200593A/es
Priority to CR20200592A priority patent/CR20200592A/es
Priority to CN201680071930.3A priority patent/CN108602867A/zh
Priority to BR112018007206-0A priority patent/BR112018007206A2/pt
Priority to HK19101744.6A priority patent/HK1259376A1/zh
Priority to JP2018516122A priority patent/JP7053457B2/ja
Priority to SG10202111398UA priority patent/SG10202111398UA/en
Priority to EP16805348.6A priority patent/EP3387008A1/en
Priority to SG10202005498VA priority patent/SG10202005498VA/en
Priority to EA201891074A priority patent/EA201891074A1/ru
Priority to ARP160103738A priority patent/AR106920A1/es
Priority to US15/375,070 priority patent/US10398766B2/en
Priority to TW109140683A priority patent/TW202126676A/zh
Priority to TW105140762A priority patent/TWI658050B/zh
Priority to US15/374,480 priority patent/US10117916B2/en
Priority to US15/374,054 priority patent/US10064928B2/en
Priority to TW108109253A priority patent/TWI730306B/zh
Priority to ZA2018/01752A priority patent/ZA201801752B/en
Priority to PH12018500848A priority patent/PH12018500848A1/en
Priority to CONC2018/0004865A priority patent/CO2018004865A2/es
Priority to IL259304A priority patent/IL259304A/en
Priority to CL2018001532A priority patent/CL2018001532A1/es
Priority to US16/054,503 priority patent/US11083784B2/en
Priority to US16/109,406 priority patent/US10238724B2/en
Priority to US16/109,451 priority patent/US10335474B2/en
Priority to US16/109,436 priority patent/US10238726B2/en
Priority to US16/109,427 priority patent/US10238725B2/en
Priority to US16/415,655 priority patent/US10653761B2/en
Priority to US16/415,671 priority patent/US10653762B2/en
Priority to US16/669,622 priority patent/US10722566B2/en
Priority to CL2020001989A priority patent/CL2020001989A1/es
Priority to CL2020001987A priority patent/CL2020001987A1/es
Priority to CL2020001986A priority patent/CL2020001986A1/es
Priority to CL2020001985A priority patent/CL2020001985A1/es
Priority to CL2020001988A priority patent/CL2020001988A1/es
Priority to AU2020281108A priority patent/AU2020281108B2/en
Priority to US17/320,854 priority patent/US11260115B1/en
Priority to JP2021201297A priority patent/JP2022058349A/ja
Priority to AU2022200616A priority patent/AU2022200616A1/en
Priority to US17/665,117 priority patent/US20220226450A1/en
Priority to US18/647,775 priority patent/US20240285738A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
GBGB1521746.6A 2015-12-10 2015-12-10 Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers Ceased GB201521746D0 (en)

Priority Applications (56)

Application Number Priority Date Filing Date Title
GBGB1521746.6A GB201521746D0 (en) 2015-12-10 2015-12-10 Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
MX2018005372A MX2018005372A (es) 2015-12-10 2016-11-24 Peptidos novedosos y combinacion de peptidos para usarse en la inmunoterapia contra la leucemia linfocitica cronica (cll) y otros tipos de cancer.
CR20200594A CR20200594A (es) 2015-12-10 2016-11-24 NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA LA LEUCEMIA LINFOCÍTICA CRÓNICA (LLC) Y OTROS TIPOS DE CÁNCER (Divisional 2018-0295)
MA42072A MA42072A1 (fr) 2015-12-10 2016-11-24 Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre la cll et d'autres cancers
PCT/EP2016/078718 WO2017097602A1 (en) 2015-12-10 2016-11-24 Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
CA3005813A CA3005813A1 (en) 2015-12-10 2016-11-24 Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
UAA201803219A UA124575C2 (uk) 2015-12-10 2016-11-24 Пептид для лікування раку
CR20180295A CR20180295A (es) 2015-12-10 2016-11-24 Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer
CR20200595A CR20200595A (es) 2015-12-10 2016-11-24 NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA LA LEUCEMIA LINFOCÍTICA CRÓNICA (LLC) Y OTROS TIPOS DE CÁNCER (Divisional 2018-0295)
MA043399A MA43399A (fr) 2015-12-10 2016-11-24 Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre la cll et d'autres cancers
CR20200596A CR20200596A (es) 2015-12-10 2016-11-24 NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA LA LEUCEMIA LINFOCÍTICA CRÓNICA (LLC) Y OTROS TIPOS DE CÁNCER (Divisional 2018-0295)
PE2018000324A PE20181075A1 (es) 2015-12-10 2016-11-24 Nuevos pepticos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia linfocitica cronica (llc) y otros tipos de cancer
AU2016368981A AU2016368981B2 (en) 2015-12-10 2016-11-24 Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
KR1020187013544A KR20180086190A (ko) 2015-12-10 2016-11-24 만성 림프구성 백혈병 및 다른 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
SG11201801670YA SG11201801670YA (en) 2015-12-10 2016-11-24 Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
CR20200593A CR20200593A (es) 2015-12-10 2016-11-24 NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA LA LEUCEMIA LINFOCÍTICA CRÓNICA (LLC) Y OTROS TIPOS DE CÁNCER (Divisional 2018-0295)
CR20200592A CR20200592A (es) 2015-12-10 2016-11-24 NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA LA LEUCEMIA LINFOCÍTICA CRÓNICA (LLC) Y OTROS TIPOS DE CÁNCER (Divisional 2018-0295)
CN201680071930.3A CN108602867A (zh) 2015-12-10 2016-11-24 用于cll和其他癌症免疫治疗的新型肽和肽组合物
BR112018007206-0A BR112018007206A2 (pt) 2015-12-10 2016-11-24 peptídeos e combinações de peptídeos para uso em imunoterapia contra leucemia linfocítica crônica (cll) e outros cânceres
HK19101744.6A HK1259376A1 (zh) 2015-12-10 2016-11-24 用於cll和其他癌症免疫治疗的新型肽和肽组合物
JP2018516122A JP7053457B2 (ja) 2015-12-10 2016-11-24 Ｃｌｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
SG10202111398UA SG10202111398UA (en) 2015-12-10 2016-11-24 Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
EP16805348.6A EP3387008A1 (en) 2015-12-10 2016-11-24 Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
SG10202005498VA SG10202005498VA (en) 2015-12-10 2016-11-24 Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
EA201891074A EA201891074A1 (ru) 2015-12-10 2016-11-24 Новые пептиды и комбинации пептидов для применения в иммунотерапии хлл и других видов рака
ARP160103738A AR106920A1 (es) 2015-12-10 2016-12-06 Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer
US15/375,070 US10398766B2 (en) 2015-12-10 2016-12-09 Peptides and combination of peptides for use in immunotherapy against CLL and other cancers
TW109140683A TW202126676A (zh) 2015-12-10 2016-12-09 用於抗cll及其他癌症之免疫治療的新穎胜肽及胜肽組合物
TW105140762A TWI658050B (zh) 2015-12-10 2016-12-09 用於抗cll及其他癌症之免疫治療的新穎胜肽及胜肽組合物
US15/374,480 US10117916B2 (en) 2015-12-10 2016-12-09 Peptides and combination of peptides for use in immunotherapy against CLL and other cancers
US15/374,054 US10064928B2 (en) 2015-12-10 2016-12-09 Peptides and combination of peptides for use in immunotherapy against CLL and other cancers
TW108109253A TWI730306B (zh) 2015-12-10 2016-12-09 用於抗cll及其他癌症之免疫治療的新穎胜肽及胜肽組合物
ZA2018/01752A ZA201801752B (en) 2015-12-10 2018-03-14 Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
PH12018500848A PH12018500848A1 (en) 2015-12-10 2018-04-20 Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
CONC2018/0004865A CO2018004865A2 (es) 2015-12-10 2018-05-08 Péptidos y combinaciones de péptidos para inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer
IL259304A IL259304A (en) 2015-12-10 2018-05-13 Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
CL2018001532A CL2018001532A1 (es) 2015-12-10 2018-06-08 Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer
US16/054,503 US11083784B2 (en) 2015-12-10 2018-08-03 Peptides and combination of peptides for use in immunotherapy against CLL and other cancers
US16/109,406 US10238724B2 (en) 2015-12-10 2018-08-22 Peptides and combination of peptides for use in immunotherapy against CLL and other cancers
US16/109,451 US10335474B2 (en) 2015-12-10 2018-08-22 Peptides and combination of peptides for use in immunotherapy against CLL and other cancers
US16/109,436 US10238726B2 (en) 2015-12-10 2018-08-22 Peptides and combination of peptides for use in immunotherapy against CLL and other cancers
US16/109,427 US10238725B2 (en) 2015-12-10 2018-08-22 Peptides and combination of peptides for use in immunotherapy against CLL and other cancers
US16/415,655 US10653761B2 (en) 2015-12-10 2019-05-17 Peptides and combination of peptides for use in immunotherapy against CLL and other cancers
US16/415,671 US10653762B2 (en) 2015-12-10 2019-05-17 Peptides and combination of peptides for use in immunotherapy against CLL and other cancers
US16/669,622 US10722566B2 (en) 2015-12-10 2019-10-31 Peptides and combination of peptides for use in immunotherapy against CLL and other cancers
CL2020001989A CL2020001989A1 (es) 2015-12-10 2020-07-30 Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer. (divisional solicitud 201801532)
CL2020001987A CL2020001987A1 (es) 2015-12-10 2020-07-30 Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer. (divisional solicitud 201801532)
CL2020001986A CL2020001986A1 (es) 2015-12-10 2020-07-30 Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer. (divisional solicitud 201801532)
CL2020001985A CL2020001985A1 (es) 2015-12-10 2020-07-30 Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer. (divisional solicitud 201801532)
CL2020001988A CL2020001988A1 (es) 2015-12-10 2020-07-30 Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer. (divisional solicitud 201801532)
AU2020281108A AU2020281108B2 (en) 2015-12-10 2020-12-03 Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
US17/320,854 US11260115B1 (en) 2015-12-10 2021-05-14 Peptides and combination of peptides for use in immunotherapy against CLL and other cancers
JP2021201297A JP2022058349A (ja) 2015-12-10 2021-12-11 Ｃｌｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
AU2022200616A AU2022200616A1 (en) 2015-12-10 2022-01-31 Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
US17/665,117 US20220226450A1 (en) 2015-12-10 2022-02-04 Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
US18/647,775 US20240285738A1 (en) 2015-12-10 2024-04-26 Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1521746.6A GB201521746D0 (en) 2015-12-10 2015-12-10 Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers

Publications (1)

Publication Number Publication Date
GB201521746D0 true GB201521746D0 (en) 2016-01-27

Family

ID=55274485

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1521746.6A Ceased GB201521746D0 (en) 2015-12-10 2015-12-10 Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers

Country Status (25)

Country Link
US (14) US10117916B2 (https=)
EP (1) EP3387008A1 (https=)
JP (2) JP7053457B2 (https=)
KR (1) KR20180086190A (https=)
CN (1) CN108602867A (https=)
AR (1) AR106920A1 (https=)
AU (3) AU2016368981B2 (https=)
BR (1) BR112018007206A2 (https=)
CA (1) CA3005813A1 (https=)
CL (6) CL2018001532A1 (https=)
CO (1) CO2018004865A2 (https=)
CR (6) CR20200593A (https=)
EA (1) EA201891074A1 (https=)
GB (1) GB201521746D0 (https=)
HK (1) HK1259376A1 (https=)
IL (1) IL259304A (https=)
MA (2) MA43399A (https=)
MX (1) MX2018005372A (https=)
PE (1) PE20181075A1 (https=)
PH (1) PH12018500848A1 (https=)
SG (3) SG10202005498VA (https=)
TW (2) TWI658050B (https=)
UA (1) UA124575C2 (https=)
WO (1) WO2017097602A1 (https=)
ZA (1) ZA201801752B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3004830A1 (en) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
SG11201909058WA (en) 2017-04-10 2019-10-30 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
EA201992416A1 (ru) 2017-04-10 2020-02-25 Имматикс Байотекнолоджиз Гмбх Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
LT3428194T (lt) 2017-07-14 2021-12-10 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
CN108079285B (zh) * 2018-02-06 2021-01-01 昆明龙津药业股份有限公司 用于蛇毒酶制剂的门冬氨酸稳定剂及制备方法
BR112020016176A2 (pt) 2018-02-09 2022-02-22 Immatics Us Inc Métodos de transdução de uma célula t, célula t transduzida geneticamente, composição farmacêutica, métodos de preparação de uma população de células t e uso da célula t
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
WO2020243134A1 (en) 2019-05-27 2020-12-03 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
US12011459B2 (en) 2019-06-06 2024-06-18 Immatics US, Inc. Methods for manufacturing T cells by direct sorting and compositions thereof
EP3994156A1 (en) * 2019-07-05 2022-05-11 The Francis Crick Institute Limited Novel cancer antigens and methods
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
CA3168729A1 (en) 2020-02-24 2021-09-02 Melinda MATA Methods for expanding t cells for the treatment of cancer and related malignancies
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2021207826A1 (en) * 2020-04-14 2021-10-21 Université de Montréal Novel tumor-specific antigens for acute lymphoblastic leukemia (all) and uses thereof
EP3907284A1 (en) * 2020-05-06 2021-11-10 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptides and combinations of peptides for use in immunotherapy against hematologic neoplasms and other cancers
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
TW202241938A (zh) 2020-12-31 2022-11-01 美商英麥提克斯股份有限公司 Ｃｄ８多肽、組合物及其使用方法
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
JP2024534825A (ja) 2021-08-24 2024-09-26 イマティクス ユーエス，アイエヌシー． 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡
WO2023056240A2 (en) 2021-09-28 2023-04-06 Frontaim Biomedicines, Inc. Multiple formats of molecular complexes
EP4448108A1 (en) 2021-11-08 2024-10-23 Immatics Biotechnologies GmbH Adoptive cell therapy combination treatment and compositions thereof
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
EP4514829A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023215825A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
WO2024223849A1 (en) * 2023-04-27 2024-10-31 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Neoepitope immunogenic peptides for cancer treatment and diagnosis
WO2025021979A1 (en) 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
CN121358777A (zh) 2023-07-27 2026-01-16 伊玛提克斯生物技术有限公司 抗mageb2的抗原结合蛋白
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2026033136A1 (en) 2024-08-09 2026-02-12 Immatics Biotechnologies Gmbh Advanced treatment modalities for anti-prame tcr-engineered immune cells

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0756604A1 (en) 1994-04-22 1997-02-05 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Melanoma antigens
US20040005561A1 (en) * 2000-03-01 2004-01-08 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
DE10225144A1 (de) 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US20040000556A1 (en) * 2003-01-25 2004-01-01 Harris Jennifer Hope Trash receptacles that use plastic grocery bags as liners and methods of advertising
WO2004082617A2 (en) 2003-03-14 2004-09-30 Ppd Biomarker Discovery Sciences, Llc Biological markers for diagnosing rheumatoid arthritis
WO2005076009A2 (en) * 2004-01-28 2005-08-18 Immatics Biotechnologies Gmbh Method for identifying and quantifying of tumour-associated peptides
EP1642905B1 (en) 2004-10-02 2009-01-21 Immatics Biotechnologies GmbH Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
US7608413B1 (en) * 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
WO2007103770A2 (en) 2006-03-02 2007-09-13 Ppd Biomarker Discovery Sciences, Llc Compositions and methods for analyzing renal cancer
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
JP2011502484A (ja) * 2007-11-01 2011-01-27 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｈｌａ−ｄｒ結合性ペプチドおよびそれらの使用
ES2532896T5 (es) * 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
US20110151494A1 (en) 2008-06-30 2011-06-23 H. Lee Moffit Cancer & Research Institute Methods and materials for monitoring myeloma using quantitative mass spectrometry
RS53782B1 (sr) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
WO2011027311A2 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2011027308A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
EP2330122A1 (en) * 2009-12-02 2011-06-08 Asklepios Kliniken Hamburg Gmbh OFA/iLRP derived modified peptide
WO2011073905A1 (en) * 2009-12-14 2011-06-23 Koninklijke Philips Electronics N.V. Novel tumor markers
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201014033D0 (en) * 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
CA2821582A1 (en) 2010-12-14 2012-06-21 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2013019634A1 (en) 2011-07-29 2013-02-07 University Of Georgia Research Foundation, Inc. Alpha toxin detection of gpi anchored proteins
WO2013037972A1 (en) * 2011-09-16 2013-03-21 Pamgene B.V. Method for predicting response to endocrine therapy
CA2880331A1 (en) * 2012-08-15 2014-02-20 Universite De Montreal Method for identifying novel minor histocompatibility antigens
TWI636065B (zh) 2013-08-05 2018-09-21 伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
MA54884A (fr) * 2015-07-01 2022-01-12 Immatics Biotechnologies Gmbh Neuartige peptide und kombination aus peptiden zur verwendung in der immuntherapie gegen ovarialkarzinom und andere karzinome
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers

Also Published As

Publication number Publication date
AU2016368981B2 (en) 2020-12-10
SG10202005498VA (en) 2020-07-29
CL2020001986A1 (es) 2020-12-11
TW201936210A (zh) 2019-09-16
CR20200593A (es) 2021-01-20
CR20180295A (es) 2018-09-04
US20190314476A1 (en) 2019-10-17
PE20181075A1 (es) 2018-07-04
KR20180086190A (ko) 2018-07-30
US10398766B2 (en) 2019-09-03
US10238725B2 (en) 2019-03-26
TWI658050B (zh) 2019-05-01
SG10202111398UA (en) 2021-11-29
CO2018004865A2 (es) 2018-11-30
AU2016368981A1 (en) 2018-04-12
US20180353584A1 (en) 2018-12-13
CL2020001987A1 (es) 2020-12-11
MA42072A1 (fr) 2018-12-31
CA3005813A1 (en) 2017-06-15
CL2018001532A1 (es) 2018-07-13
CR20200596A (es) 2021-01-20
HK1259376A1 (zh) 2019-11-29
JP2019502360A (ja) 2019-01-31
US20180344825A1 (en) 2018-12-06
US20170165340A1 (en) 2017-06-15
AU2020281108A1 (en) 2021-01-07
EP3387008A1 (en) 2018-10-17
CN108602867A (zh) 2018-09-28
US10238726B2 (en) 2019-03-26
CR20200592A (es) 2021-01-20
UA124575C2 (uk) 2021-10-13
US10722566B2 (en) 2020-07-28
US20170173131A1 (en) 2017-06-22
PH12018500848A1 (en) 2018-10-01
US20180353586A1 (en) 2018-12-13
US10064928B2 (en) 2018-09-04
US10653761B2 (en) 2020-05-19
TWI730306B (zh) 2021-06-11
BR112018007206A2 (pt) 2018-10-16
CR20200595A (es) 2021-01-20
MA43399A (fr) 2018-10-17
MX2018005372A (es) 2018-06-06
US20240285738A1 (en) 2024-08-29
CL2020001985A1 (es) 2020-12-11
US10653762B2 (en) 2020-05-19
US20190314475A1 (en) 2019-10-17
AU2020281108B2 (en) 2022-02-24
US20180353585A1 (en) 2018-12-13
WO2017097602A1 (en) 2017-06-15
CR20200594A (es) 2021-01-20
AR106920A1 (es) 2018-02-28
CL2020001989A1 (es) 2020-12-11
US20170165337A1 (en) 2017-06-15
JP7053457B2 (ja) 2022-04-12
US20220226450A1 (en) 2022-07-21
US10335474B2 (en) 2019-07-02
US10117916B2 (en) 2018-11-06
CL2020001988A1 (es) 2020-12-11
EA201891074A1 (ru) 2018-10-31
US10238724B2 (en) 2019-03-26
IL259304A (en) 2018-07-31
US20200054727A1 (en) 2020-02-20
SG11201801670YA (en) 2018-06-28
US20180353583A1 (en) 2018-12-13
US11260115B1 (en) 2022-03-01
AU2022200616A1 (en) 2022-02-24
US11083784B2 (en) 2021-08-10
TW201720842A (zh) 2017-06-16
ZA201801752B (en) 2019-01-30
JP2022058349A (ja) 2022-04-12

Similar Documents

Publication Publication Date Title
ZA201801752B (en) Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
SG10202101368WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
SG11201706681VA (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
SG10202007962RA (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers
GB201511792D0 (en) Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
GB201604458D0 (en) Peptides and combination of peptides for use in immunotherapy against cancers
IL258599A (en) New peptides and a combination of peptides used in immunotherapy against breast cancer and other types of cancer
ZA201707942B (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG10202001404VA (en) Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
SG10202001665QA (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG10202005950XA (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
ZA201707810B (en) Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
SG10202001660YA (en) Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201517538D0 (en) Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
IL254129A0 (en) New peptides and a combination of peptides for use in immunotherapy against various tumors
GB201604490D0 (en) Peptides combination of peptides for use in immunotherapy against cancers
IL254081B (en) New peptides and a combination of peptides for immunotherapeutic use against pancreatic cancer and other types of cancer
SG10202110335PA (en) Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
ZA201805512B (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers
HK40000403A (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)